Genetic Information
Gene & Transcript Details
| ID | Status | Details |
|---|---|---|
| NM_001330437.2 | Alternative | 6085 nt | 166–1959 |
| NM_001330437.1 | Alternative | 6151 nt | 215–2008 |
Variant Details
Clinical & Population Data
Population Frequency
gnomADClinVar
OpenVariant summary: PTPN11 c.1052G>A (p.Arg351Gln) results in a conservative amino acid change located in the PTP type protein phosphatase domain (IPR000242) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00043 in 251446 control chromosomes. The observed variant frequency is approximately 6.81 fold of the estimated maximal expected allele frequency for a pathogenic variant in PTPN11 causing Noonan Syndrome phenotype (6.3e-05), strongly suggesting that the variant is benign. To our knowledge, no occurrence of c.1052G>A in individuals affected with Noonan Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. Two clinical diagnostic laboratories and an expert panel (ClinGen RASopathy Variant Curation Expert Panel) have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (benign/likely benign, n=2; VUS, n=1). Based on the evidence outlined above, the variant was classified as benign.
"This variant has been reported in ClinVar as Benign (5 clinical laboratories) and as Uncertain significance (1 clinical laboratories) and as Likely benign (1 clinical laboratories) and as Benign by ClinGen RASopathy Variant Curation Expert Panel expert panel."
COSMIC Somatic Evidence
Open
Functional Impact & Domains
Functional Domain
Error in OpenAI Consolidation. OncoKB: PTPN11R351QPTPN11R351QSomaticNCBI Gene:5781|Show additional gene information Variant OverviewPTPN11, a protein tyrosine phosphatase, is altered in various solid and hematologic malignancies.There is no available functional data about the PTPN11 R351Q mutation (last reviewed on 04/06/2017), and therefore its biological significance is unknown. JAX-CKB: No results found
Click on previews to view full database entries. External databases may require institutional access.
Computational Analysis
Pathogenicity Predictions
SpliceAISpliceAI Scores
Window: ±500bp| Effect Type | Score | Position |
|---|---|---|
| Acceptor Loss (AL) | 0.0 | -140 bp |
| Donor Loss (DL) | 0.0 | 40 bp |
| Acceptor Gain (AG) | 0.0 | 3 bp |
| Donor Gain (DG) | 0.0 | -41 bp |
VCEP Guidelines
Applied ACMG/AMP Criteria (VCEP Specific)
PM2 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
BP4 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)